197509-46-9

197509-46-9 structure

Name: Laniquidar
Chemical Name: methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
CAS Number: 197509-46-9
Molecular Formula: C₃₇H₃₆N₄O₃
Molecular Weight: 584.71
Catalog: Signaling Pathways Membrane Transporter/Ion Channel P-glycoprotein
Create Date: 2016-01-09 06:37:32
Modify Date: 2024-01-07 20:28:25
Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters[1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[2]. Laniquidar has limited oral bioavailability[3].

Name	methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
Synonyms	Laniquidar 5H-Imidazo(2,1-b)(3)benzazepine-3-carboxylic acid,6,11-dihydro-11-(1-(2-(4-(2-quinolinylmethoxy)phenyl)ethyl)-4-piperidinylidene)-,methyl ester Laniquidar [INN] UNII-K3FRN4DDOY

Description	Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters[1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[2]. Laniquidar has limited oral bioavailability[3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Membrane Transporter/Ion Channel >> P-glycoprotein
Target	IC50: 0.51 μM (P-glycoprotein)[1]
References	[1]. Luurtsema G, et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9. [2]. Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51. [3]. Fox E, et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59.